Swedish monitoring systems developer Senzime has started a clinical study of its CliniSenz System for monitoring the lactate levels in patients who have undergone surgery for esophageal cancer.
CliniSenz System is a combination of the firm’s CliniSenz Analyser and OnZurf Probe.
CliniSenz Analyser allows remote patient monitoring, needs a small volume of samples for analysis and can be used for early identification of complications and diagnosis.
Compatible with microdialysis catheters such as OnZurf Probe, the analyser features an enzyme-based heat flow detection incorporated on a microfluidic chip, which aids in avoiding substance interferences.
Designed for continuous sampling and collection of biomarkers, Onzurf Probe comes with an attachment site, which enables placement on the surface of an organ without penetration or pressure.
The microdialysis sampler can be used with analytical systems such as Clinisenz Analyser and high-performance liquid chromatography (HPLC).
Senzime CEO Lena Söderström said: “The clinical market is looking for systems that allow continuous monitoring of biomarkers in blood and tissues to rapidly detect post-operative complications and to guide timely interventions.
“Effective monitoring systems are necessary in order to reduce the number of painful and care-intensive complications after surgery.”
Being conducted at the Uppsala University Hospital, the trial will use the system to assess the local lactate levels in esophageal cancer patients after surgery, for early identification of signs of leakage before detection by standard diagnostics.
It is reported that initial assessments from the trial are expected to be revealed after enrolling 20 patients.
The early detection is expected to allow faster intervention and prevention of complications after the surgery.
Image: CliniSenz Analyzer. Photo: courtesy of Senzime.